On Cusp of Merck Acquisition, Seagen Makes Waves in Colorectal Cancer
Seagen recently presented positive pivotal Phase II data from its trial of Tukysa (tucatinib) in combination with trastuzumab in HER2-positive metastatic colorectal cancer.
Source: biospace.com